Abstract:Chimeric antigen receptor (CAR) T-cell therapy has encountered limited success in solid tumors. The lack of dependable antigens and the immunosuppressive tumor microenvironment (TME) are major challenges. Within the TME, tumor cells along with immunosuppressive cells employ an immune-evasion mechanism that upregulates programmed death ligand 1 (PD-L1) to deactivate effector T cells; this makes PD-L1 a reliable, universal target for solid tumors. We developed a novel PD-L1 CAR (MC9999) using our humanized anti-PD-L1 monoclonal antibody, designed to simultaneously target tumor and immunosuppressive cells. The antigen-specific antitumor effects of MC9999 CAR T-cells were observed consistently across four solid tumor models: breast cancer, lung cancer, melanoma, and glioblastoma multiforme (GBM). Notably, intravenous administration of MC9999 CAR T-cells eradicated intracranially established LN229 GBM tumors, suggesting penetration of the blood-brain barrier. The proof-of-concept data demonstrate the cytolytic effect of MC9999 CAR T-cells against immunosuppressive cells, including microglia HMC3 cells and M2 macrophages. Furthermore, MC9999 CAR T-cells elicited cytotoxicity against primary tumor-associated macrophages within GBM tumors. The concept of targeting both tumor and immunosuppressive cells with MC9999 was further validated using CAR T-cells derived from cancer patients. These findings establish MC9999 as a foundation for the development of effective CAR T-cell therapies against solid tumors.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are the two major challenges faced by CAR - T cell therapy in the treatment of solid tumors: the lack of reliable tumor antigens and the immunosuppressive tumor microenvironment (TME). Specifically: 1. **Lack of reliable tumor antigens**: Unlike hematological malignancies, the antigen heterogeneity in solid tumors is high, and it is difficult to find a universally applicable target. This poses a huge challenge for the application of CAR - T cells in solid tumors. 2. **Immunosuppressive tumor microenvironment (TME)**: Immunosuppressive cells in solid tumors (such as regulatory T cells, myeloid - derived suppressor cells, etc.) inhibit the function of effector T cells by up - regulating programmed death ligand 1 (PD - L1), thereby helping tumor cells escape the attack of the immune system. This mechanism further weakens the efficacy of CAR - T cells. To solve these problems, researchers have developed a new type of PD - L1 - targeted CAR - T cell (named MC9999), aiming to simultaneously attack PD - L1 - expressing tumor cells and immunosuppressive cells. In this way, MC9999 CAR - T cells can not only directly kill tumor cells, but also disrupt the PD - L1 - mediated immunosuppressive network in the tumor microenvironment, thereby enhancing the anti - tumor effect. ### Key content summary: - **Background**: CAR - T cell therapy has achieved remarkable success in hematological malignancies, but its application in solid tumors is limited. - **Problem**: The lack of reliable antigens and the immunosuppressive microenvironment in solid tumors are the main obstacles. - **Solution**: Develop PD - L1 - targeted CAR - T cells (MC9999) to simultaneously attack tumor cells and immunosuppressive cells. - **Experimental results**: MC9999 CAR - T cells have shown significant anti - tumor effects in multiple solid tumor models and can penetrate the blood - brain barrier to effectively clear intracranial GBM tumors. - **Future prospects**: This study provides new ideas and directions for the development of effective CAR - T cell therapies for solid tumors. Through these studies, the authors hope that MC9999 CAR - T cells can become a potential immunotherapy method for treating multiple types of solid tumors.

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment